Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Clin Gastroenterol Hepatol. 2014 Oct 5;13(2):336–338. doi: 10.1016/j.cgh.2014.09.045

Figure 2. Criteria for Use of Accelerated Dosing of Infliximab.

Figure 2

More than two thirds of respondents used solely clinical criteria to decide which patients should receive accelerated dosing of infliximab, though many included biomarkers including CRP, ESR, fecal calprotectin, albumin, and infliximab levels when available.